Articles tagged with Host Proteins
Scientists have identified a new target to prevent cold sores by understanding how the herpes virus triggers its own immune response. The discovery has important implications for genital herpes caused by the same virus, with potential treatments in development.
Researchers discover SARS-CoV-2 hijacks three host proteins to shield itself from complement-mediated lysis, significantly impairing viral clearance. This may affect the course of acute and post-COVID-19 sequelae, deepening our understanding of immune evasion mechanisms.
Researchers discovered that ZC3H11A is essential for regulating metabolic genes in embryos and their absence leads to complete lethality. The study's findings suggest that ZC3 may be a promising therapeutic target for the development of anti-viral agents against medically significant human viruses.
Researchers discovered host proteins APOBEC3 can aid HIV's latency, a major hurdle to cure research. The finding raises questions about the role of these proteins and potential ways to block their activity to inhibit viral persistence.
A comprehensive study reveals SARS-CoV-2 viral-to-human protein interaction network, showing how the virus hijacks human proteins. Researchers identified 23 candidate drugs, including an FDA-approved beta-blocker that shows promise in inhibiting viral infection.
A Cleveland Clinic-led research team created a discovery tool outlining interactions between COVID-19 and host proteins, identifying potential host-targeting therapies. The study confirmed over 200 interactions and discovered new ones, highlighting promising approaches for treating COVID-19.
Researchers at La Jolla Institute for Immunology have identified a critical protein, GSPT1, that facilitates Lassa virus infection. Targeting this protein with an existing drug candidate, CC-90009, shows promise in reducing Lassa virus growth without cell toxicity.
A team of scientists from the University of Bristol has identified a host cell pathway hijacked by SARS-CoV-2, allowing it to penetrate human cells. The study found that removing a protein complex called ESCPE-1 blocks COVID-19 infection by around 50%.
A research team has discovered how the Covid virus reproduces itself by taking over the cell's protein factory. The team identified a specific structure in viral mRNA that allows the virus to access the ribosome and produce its own proteins, while blocking cellular production. This discovery opens up new avenues for antiviral treatments.
A UBC-led research team discovered that SARS-CoV-2 attaches to and deactivates galectin-8, a sensor protein that protects cells against infection. By disabling this defense system, the virus can hijack host cells to produce more viruses.
Researchers from Nara Institute of Science and Technology developed a machine learning program that accurately predicts the location of proteins related to actin in cells. The program achieved a high degree of similarity with actual images, showing promise for future applications in cell analysis and artificial cell staining.
This year's award recipients demonstrate substantial and lasting impact on protein science, with notable achievements in education, technological advancement, and structural biology. Professor Sheila Jaswal and Petra Fromme are recognized for their exceptional contributions to protein research and education.
Scientists have created a global atlas of direct interactions between SARS-CoV-2 RNA and the human proteome, revealing 18 key host proteins involved in viral replication. The study also identified two crucial regulators, CNBP and LARP1, which can inhibit viral replication, offering new avenues for treatment.
Aarthi Narayanan is studying Brilacidin's direct virus-killing activity and its potential as a second dose to infected cells. The researchers aim to determine the optimal timing of treatment using this investigational antibiotic.
Researchers at Kanazawa University found that inactivating the mosquito salivary protein AAPP significantly reduces mosquito feeding behavior, prolonging probing times and fluid excretion. This reduces egg production but does not affect malarial parasite development.
A team of researchers at Texas Biomed has identified the interaction between an Ebola virus protein and a human cell protein that may be crucial to understanding the virus's life cycle. By studying this interaction in human cells using live virus, the scientists hope to develop potential drug targets to stop the disease.
Researchers found a new mechanism by which small snoRNAs regulate the splicing process of host genes, ensuring proper protein production. This breakthrough discovery opens a new avenue of research into gene expression and has implications for understanding diseases like cancer.
A new study reveals how plant-rotting bacteria obtain essential iron for survival by pirating it from host plants' iron-bearing proteins. The bacterium Pectobacterium uses a membrane channel to import the protein ferredoxin, which is then processed to release iron.
Researchers discovered a parasite-derived protein, H-IPSE, with potent therapeutic effects on chemotherapy-induced hemorrhagic cystitis in mice. The study found that H-IPSE alters host cell transcription, suggesting a novel approach to treating bladder pain and injury.
A Kansas State University study finds a naturally occurring mutation in the myxoma virus weakens it and allows rabbits to resist infection. The researchers hope this discovery will aid in understanding pathogen evolution and predicting which viruses pose threats to humans.
A recent study identified 20 previously unknown host molecules that enable influenza A viruses to replicate and spread. Blocking these host proteins can inhibit viral growth and slow disease progression in mice. The researchers developed a public web portal to facilitate drug development and analysis of host-protein interactions.
Two deadly viruses, hepatitis C and Kaposi's sarcoma-associated herpesvirus, were found to target common host proteins that are critical for human biology. By studying protein interactions between viruses and cells, scientists have identified potential new targets for anti-viral treatments.
Researchers at the Washington University School of Medicine identified how Ebola dodges antiviral defenses by hijacking a host protein's ability to carry an important immune signal. This finding could lead to new therapies targeting the virus's deadliness.
Researchers have discovered a mechanism that targets a protein called ERGIC-53, which is essential for the replication of arenaviruses and interacts with other pathogenic viruses. The findings suggest that targeting ERGIC-53 could result in an immunizing form of antiviral therapy.
Researchers at the University of California - San Diego discovered a structural basis for how strep protein can trigger toxic shock. The proteins form dense scaffolds that mimic blood clots, leading to widespread inflammation and organ failure. This breakthrough provides new insights into the pathogenesis of strep-induced toxic shock.
Researchers at the University of Pennsylvania have identified a protein, ISG15, that slows down the spread of Ebola virus by blocking its ability to escape from cells. This finding offers promise for future treatments against Ebola outbreaks.
A team of UCSD researchers has identified a 24-member family of bacterial proteins called effector proteins that help pathogenic bacteria such as Salmonella and E-coli infect human cells by hijacking the body's communication network. The findings could lead to novel ways to fight bacterial diseases.
Researchers at UNC have discovered that CIB1 inhibits cell migration in cancer cells by activating PAK1, a kinase that adds phosphate groups to other proteins. This finding suggests that CIB1 may be a potential target for developing new treatments to decrease tumor metastasis.
A team from Pacific Northwest National Laboratory and Oregon Health & Science University has discovered a record number of proteins for the highly infectious human cytomegalovirus, doubling the previously identified amount. The study reveals that HCMV may express as many as 200 proteins at various points in its life cycle.
Researchers develop a technique to conjugate peptides to virus-like particles, generating high-titer antibodies that inhibit disease-causing cytokines. This approach shows promise in blocking or delaying onset of autoimmune diseases such as arthritis.